GOSS Gossamer Bio, Inc.

Gossamer Bio, Inc. (NASDAQ:GOSS) announced a structured private placement on August 21 that could generate up to approximately $250 million in gross proceeds. However, Gossamer Bio, Inc. (NASDAQ:GOSS) divided the financing into three stages, leaving most of the headline amount dependent on regulatory milestones. At the initial closing, Gossamer Bio, Inc. (NASDAQ:GOSS) expects approximately $25 […]

The proceeds will help advance seralutinib's clinical development and potential commercialisation.

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S

Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertension drug receives FDA approval. Key Investor TakeawaysGossamer Bio (NASDAQ:GOSS) has secured up to $250 million through a structured private placement tied to seralutinib’s regulatory progress.

Gossamer Bio (GOSS) shares were up 10% in Friday's premarket trading after the company said it has a

For Gossamer Bio, the average analyst Fair Value has shifted from about US$3.86 to about US$1.66 per share, which marks a meaningful reset in price targets. Research commentary links this move to a split view on risk, funding and execution, with more cautious analysts focusing on dilution and going concern warnings, while bullish voices still point to the seralutinib regulatory path and balance sheet work. As you read on, you will see how these changing assumptions shape the evolving Gossamer...

Gossamer Bio (GOSS) delivered earnings and revenue surprises of -100.00% and +171.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kura Oncology (KURA) delivered earnings and revenue surprises of +13.48% and +23.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio (GOSS) shares are in focus after the company detailed plans to submit an NDA for seralutinib in pulmonary arterial hypertension, reacquired global rights to the drug, and outlined recent shareholder approvals. See our latest analysis for Gossamer Bio. Gossamer Bio’s recent FDA meeting update and plan to submit an NDA for seralutinib have come after a tough period, with the stock’s 1 year total shareholder return down 91.53% and 5 year total shareholder return down 97.95%...

Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

(Updates with the stock move in the headline and the first two paragraphs.) Gossamer Bio's (GOSS)

Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% on Monday after the biotechnology company provided a positive regulatory update on its lead drug candidate, seralutinib, and announced it had regained full global rights to the therapy.